Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

98.47
-4.4000-4.28%
Pre-market: 99.571.10+1.12%04:11 EST
Volume:952.77K
Turnover:93.89M
Market Cap:6.57B
PE:-31.71
High:104.11
Open:103.87
Low:97.35
Close:102.87
52wk High:122.20
52wk Low:45.91
Shares:66.74M
Float Shares:53.42M
Volume Ratio:1.31
T/O Rate:1.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-4.3376
ROE:-85.79%
ROA:-26.74%
PB:44.16
PE(LYR):-22.70

Loading ...

Rhythm Pharmaceuticals CFO Hunter C. Smith Reports Sale of Common Shares

Reuters
·
Feb 07

Rhythm Pharmaceuticals CFO to Join Guggenheim Biotech Summit Fireside Chat

Reuters
·
Feb 05

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 20

Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Strong IMCIVREE Revenue Guidance For 2025

Simply Wall St.
·
Jan 19

Rhythm Pharmaceuticals price target raised to $145 from $140 at BofA

TIPRANKS
·
Jan 12

Rhythm Pharmaceuticals Inc : TD Cowen Raises Target Price to $130 From $120

THOMSON REUTERS
·
Jan 12

Rhythm Pharmaceuticals (RYTM) Receives a Buy from TD Cowen

TIPRANKS
·
Jan 10

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Jan 09

BRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results

Reuters
·
Jan 09

Rhythm Pharmaceuticals Reports Preliminary 2025 Revenue Up 50% to $194 Million

Reuters
·
Jan 09

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals Inc - Prelim Q4 2025 Imcivree Revenues About $57 Mln, up 11% From Q3

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals Inc - Topline Data From Phase 3 Emanate Trial Expected Q1 2026

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals Inc - FY 2025 Prelim Product Revenues About $194 Mln, up 50% From FY2024

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals Inc - March 20, 2026 Pdufa Goal Date for Snda for Setmelanotide in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Jan 09

Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After an 87% Year-to-Date Biotech Rally

Simply Wall St.
·
Dec 23, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 22, 2025

Rhythm Pharmaceuticals Director Camille Bedrosian Resigns

Reuters
·
Dec 20, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Dec 17, 2025

Chief Human Resources Officer Pamela J. Cramer Reports Sale of Rhythm Pharmaceuticals Common Shares

Reuters
·
Dec 16, 2025